Al Gianchetti, XyloCor CEO

Xy­lo­Cor wraps up PhII for heart dis­ease gene ther­a­py, plans for piv­otal tri­al

Xy­lo­Cor Ther­a­peu­tics says pa­tients with heart dis­ease who got its gene ther­a­py could ex­er­cise for longer and had few­er chest pain at­tacks. The biotech an­nounced it com­plet­ed a Phase I/II tri­al of the gene ther­a­py Thurs­day morn­ing, and plans to move for­ward with a piv­otal tri­al.

In the Phase II por­tion of the tri­al, 28 pa­tients with angi­na (or chest pain) caused by coro­nary artery dis­ease and who had no oth­er treat­ment op­tions were en­rolled and were giv­en the high­est test­ed dose from the first part of the tri­al. Pa­tients were fol­lowed for six months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA